(Q41441257)

30 September 2017

1 reference

title

In vivo studies with antisense oligonucleotides (English)

1 reference

30 September 2017

Akhtar S

1

1 reference

30 September 2017

Agrawal S

series ordinal

2

1 reference

30 September 2017

publication date

1 January 1997

1 reference

Trends in Pharmacological Sciences

30 September 2017

published in

1 reference

30 September 2017

volume

18

1 reference

30 September 2017

issue

1

1 reference

30 September 2017

page(s)

12-18

1 reference

The therapeutic potential of antisense oligonucleotides

30 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(96)01002-4

7 January 2021

Oligodeoxynucleotide stability in subcellular extracts and culture media

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(96)01002-4

7 January 2021

Stability of antisense DNA oligodeoxynucleotide analogs in cellular extracts and sera

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(96)01002-4

7 January 2021

Pharmacokinetics of antisense oligonucleotides

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(96)01002-4

7 January 2021

Therapeutic Applications of Oligonucleotides

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(96)01002-4

7 January 2021

Oligonucleotides antisense to the interleukin 1 receptor mRNA block the effects of interleukin 1 in cultured murine and human fibroblasts and in mice

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(96)01002-4

7 January 2021

Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(96)01002-4

7 January 2021

Ablation of transplanted HTLV-I Tax-transformed tumors in mice by antisense inhibition of NF-kappa B

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(96)01002-4

7 January 2021

Antisense oligonucleotide blocks progesterone-induced lordosis behavior in ovariectomized rats.

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(96)01002-4

7 January 2021

In vivo inhibition of duck hepatitis B virus replication and gene expression by phosphorothioate modified antisense oligodeoxynucleotides.

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(96)01002-4

7 January 2021

A single-injection protein kinase A-directed antisense treatment to inhibit tumour growth

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(96)01002-4

7 January 2021

V1 vasopressin receptor antisense oligodeoxynucleotide into septum reduces vasopressin binding, social discrimination abilities, and anxiety-related behavior in rats.

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(96)01002-4

7 January 2021

Transient decrease in high blood pressure by in vivo transfer of antisense oligodeoxynucleotides against rat angiotensinogen

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(96)01002-4

7 January 2021

Prevention of tumor formation in a mouse model of Burkitt's lymphoma by 6 weeks of treatment with anti-c-myc DNA phosphorothioate.

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(96)01002-4

7 January 2021

Antitumor effect of c-myc antisense phosphorothioate oligodeoxynucleotides on human melanoma cells in vitro and and in mice

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(96)01002-4

7 January 2021

Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(96)01002-4

7 January 2021

Capped oligodeoxynucleotide phosphorothioates. Pharmacokinetics and stability in mice

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(96)01002-4

7 January 2021

A novel oligodeoxynucleotide inhibitor of thrombin. II. Pharmacokinetics in the cynomolgus monkey.

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(96)01002-4

7 January 2021

Pharmacokinetics of an anti—human immunodeficiency virus antisense oligodeoxynucleotide phosphorothioate (GEM 91) in HIV-infected subjects*

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(96)01002-4

7 January 2021

Absorption, tissue distribution and in vivo stability in rats of a hybrid antisense oligonucleotide following oral administration

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(96)01002-4

7 January 2021

A pharmacokinetic evaluation of 14C-labeled afovirsen sodium in patients with genital warts.

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(96)01002-4

7 January 2021

Pharmacokinetics and tissue distribution in rats of an oligodeoxynucleotide phosphorothioate (GEM 91) developed as a therapeutic agent for human immunodeficiency virus type-1.

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(96)01002-4

7 January 2021

Improved cellular delivery of antisense oligonucleotides using transferrin receptor antibody-oligonucleotide conjugates

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(96)01002-4

7 January 2021

Phosphorothioate oligodeoxynucleotides: antisense or anti-protein?

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(96)01002-4

7 January 2021

In vivo stability, disposition and metabolism of a “hybrid” oligonucleotide phosphorothioate in rats

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(96)01002-4

7 January 2021

A sense phosphorothioate oligonucleotide directed to the initiation codon of transcription factor NF-kappa B p65 causes sequence-specific immune stimulation.

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(96)01002-4

7 January 2021

Immune stimulation by an antisense oligomer complementary to the rev gene of HIV-1

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(96)01002-4

7 January 2021

Ability of oligonucleotides with certain palindromes to induce interferon production and augment natural killer cell activity is associated with their base length

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(96)01002-4

7 January 2021

CpG motifs in bacterial DNA trigger direct B-cell activation

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(96)01002-4

7 January 2021

Effect of different chemically modified oligodeoxynucleotides on immune stimulation

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(96)01002-4

7 January 2021

Novel enzymatic and immunological responses to oligonucleotides

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(96)01002-4

7 January 2021

Large-scale synthesis, purification, and analysis of oligodeoxynucleotide phosphorothioates

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(96)01002-4

7 January 2021

Antisense oligonucleotides: towards clinical trials

1 reference

https://api.crossref.org/works/10.1016/S0165-6147(96)01002-4

7 January 2021

10.1016/S0165-6147(96)01002-4

Identifiers

DOI

1 reference

release_2cmeyoggqffhjcy4qrgme3xqom

30 September 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/2cmeyoggqffhjcy4qrgme3xqom

24 November 2022

mapped directly with Wikidata item

1 reference